Trademarkia Logo

Canada

C$
SULINNO
REGISTERED

on 22 Feb 2023

Last Applicant/ Owned by

INNOVENT BIOLOGICS (SUZHOU) CO. LTD.

No. 168, Dongping Street, Suzhou Industrial Park,Suzhou CityJiangsu Province

CN

Serial Number

2085288 filed on 23rd Sept 2020

Registration Number

TMA1167109 registered on 22nd Feb 2023

Registration expiry Date

23rd Sept 2030

Correspondent Address

NEOMARK LTD.

7450 rue Saint-HubertMontréal

QUEBEC

CA

H2R2N3

SULINNO

Trademark usage description

medicines for human purposes for the treatment of tumors, ophthalmology diseases, cardiovascular diseases, autoimmune diseases and disorders, immunolo Read More

Classification Information


Class [005]
Medicines for human purposes for the treatment of tumors, ophthalmology diseases, cardiovascular diseases, autoimmune diseases and disorders, immunologic deficiency syndromes, anemia, anorexia, arthritis, bulimia nervosa, gout, hyperlipidemia, hypothyroidism, insulin resistance, metabolic syndrome, muscular dystrophy, obesity, osteoarthritis, blood disorders, diabetes, growth and thyroid disorders, primary periodic paralysis, glucagonoma, disorders relating to sexual reproduction and fertility, respiratory system diseases, central nervous system [CNS] diseases, cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies, plexopathies, genetic diseases; medicines for human purposes that modulate the immune system; medicines for human purposes for regulating the immune system; medicines for human purposes being antivirals; biochemical medicines for the treatment of cancer; liquid medicines for the treatment of tumors, ophthalmology diseases, cardiovascular diseases, autoimmune diseases and disorders, immunologic deficiency syndromes, anemia, anorexia, arthritis, bulimia nervosa, gout, hyperlipidemia, hypothyroidism, insulin resistance, metabolic syndrome, muscular dystrophy, obesity, osteoarthritis, blood disorders, diabetes, growth and thyroid disorders, primary periodic paralysis, glucagonoma, disorders relating to sexual reproduction and fertility, respiratory system diseases, central nervous system [CNS] diseases, cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies, plexopathies, genetic diseases; liquid medicines for human purposes that modulate the immune system; liquid medicines for human purposes for regulating the immune system; liquid medicines for human purposes being antivirals; pharmaceutical preparations for the treatment of gastrointestinal disorders; blood substitutes; diagnostic chemical reagents for medical purposes; biological preparations for medical purposes for the treatment of osteoporosis; biological tissue cultures for veterinary purposes; drugs for medical purposes for the treatment of fever; diagnostic preparations for medical laboratory use; vaccines, namely human vaccines, veterinary vaccines; injectable solutions for medical purposes for injection for treating tuberculosis.


Classification kind code

11

Mark Details


Serial Number

2085288

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 48
on 13th Sept 2022
Agent Changed
Submitted for opposition 22
on 24th Mar 2022
Search Recorded
Submitted for opposition 20
on 24th Mar 2022
Examiner's First Report
Submitted for opposition 223
on 24th Mar 2022
Total Provisional Refusal
Submitted for opposition 256
on 20th Dec 2021
Notification of Possible Opposition Sent
Submitted for opposition 257
on 18th Feb 2021
Designation Notification - Madrid Protocol
Submitted for opposition 31
on 17th Feb 2021
Formalized
Submitted for opposition 1
on 17th Feb 2021
Created
Submitted for opposition 228
on 23rd Sept 2020
International Registration
Submitted for opposition 30
on 23rd Sept 2020
Filed